Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: American Biogenetic Sciences

This article was originally published in The Gray Sheet

Executive Summary

American Biogenetic Sciences: Plans fourth quarter launch of its FiF functional intact fibrinogen test following 510(k) clearance by FDA. FiF is intended to provide a "rapid and direct quantitative measurement of clotable levels of fibrin protein in plasma," ABS says. The clearance covers use of the product "for the testing of conditions in which blood coagulation is involved" such as "disseminated intravascular coagulation, cardiovascular disease and primary fibrinolysis." The FiF test is ABS' second commercial test; the company launched its TpP thrombus precursor protein test earlier this year following FDA clearance in late 1996 ("The Gray Sheet" Nov. 4, 1996, I&W-6)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel